SYF03e47ecc0eba45f9bc594971b02e04de

UnknownPhase 1

Single dose oral bioequivalence study of Cladribine 10 mg Ta...

PharOS Pharmaceutical Oriented Servises Ltd.Source

Compare

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

2

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 2 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
June 30, 2025
Actual (reported)

Conditions

No therapeutic indication in the current trial with healthy volunteers.

Sponsors & Collaborators

PharOS Pharmaceutical Oriented Servises Ltd.
Industrylead
CCDRD Cooperative Clinical Drug Research and Development AG
Industryco_sponsor

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Study Sites (2)

Clinic of Clinical Pharmacology and Therapeutics UMHAT 'Tsaritsa Ioanna-ISUL' EAD

Sofia, 1527, Bulgaria

Andrey Petrov+35929432152 andrewpbg@yahoo.com

Bed space for short term stay at Diagnostic & Consultative Centre 'Ascendent' Ltd.

Sofia, 1202, Bulgaria

Ivo Bogdanov+35929839494 ivoatbog@gmail.com

Central Study Contacts

Project Manager

+302106664667 fsamara@pharosgr.gr

Project Manager

+49334223790

Study Design

Study Type: interventional
Phase: phase 1

Study Record Dates

First Submitted

June 30, 2025

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2025-522252-74-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-30 06:25:24 UTC

Locations

BG(2)

SYF6ed0f8284d8b4f8889b4688057dd752f

Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

Phase 1Unknown

SYFca71c33bc66d4ea1855dc692f88042a9

Evaluation of the bioequivalence of two products containing esomeprazole under fasting conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexium 40 mg (Comparator). An open, randomized, single dose, four-period, replicate, crossover trial in healthy volunteers

Phase 1Unknown

SYFffaf13a9a9114df7b045f7d41d38485b

Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

Phase 1Unknown

SYF124052c7b7e146aa9b8a24b0f3e5e8e3

Evaluation of the bioequivalence of two intravaginal gel preparations containing 90 mg progesterone

Phase 1Not Yet Recruiting

SYFd5b65c77d98d40beb5639ad669fb7568

Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women

Phase 1Recruiting

SYF044ec59472d94215ac47522e57e4355f

Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal women

Phase 1Unknown

SYFe7deccec46914671a9d135c8bd6a44f8

Bioavailability study with naloxone hydrochloride in healthy volunteers

Phase 1Unknown

mmontag@ccdrdag.com